View in EDS

Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration.

Saved in:

Bibliographic Details
Title:	Phase 1 Study of JNJ-81201887 Gene Therapy in Geographic Atrophy Secondary to Age-Related Macular Degeneration.
Authors:	Heier JS; Ophthalmic Consultants of Boston, Boston, Massachusetts., Cohen MN; The Retina Service of Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, Pennsylvania., Chao DL; Janssen Research & Development, LLC, a Johnson & Johnson Company, Raritan, New Jersey., Pepio A; Janssen Research & Development, LLC, a Johnson & Johnson Company, Raritan, New Jersey; Janssen, Inc., Toronto, Ontario, Canada. Electronic address: apepio@its.jnj.com., Shiraga Y; Janssen Research & Development, LLC, a Johnson & Johnson Company, Raritan, New Jersey., Capuano G; Janssen Research & Development, LLC, a Johnson & Johnson Company, Raritan, New Jersey., Rogers A; Hemera Biosciences, LLC, Waltham, Massachusetts., Ackert J; Janssen Research & Development, LLC, a Johnson & Johnson Company, Raritan, New Jersey., Sen HN; Janssen Research & Development, LLC, a Johnson & Johnson Company, Raritan, New Jersey., Csaky K; Retina Foundation of the Southwest, Dallas, Texas.
Source:	Ophthalmology [Ophthalmology] 2024 Dec; Vol. 131 (12), pp. 1377-1388. Date of Electronic Publication: 2024 Jun 22.
Publication Type:	Journal Article; Clinical Trial, Phase I; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Elsevier Country of Publication: United States NLM ID: 7802443 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1549-4713 (Electronic) Linking ISSN: 01616420 NLM ISO Abbreviation: Ophthalmology Subsets: MEDLINE
Database:	MEDLINE Ultimate

Description
ISSN:	1549-4713
DOI:	10.1016/j.ophtha.2024.06.013